Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (141-150 of 206) with videos related to

Pageof 21
Sort By:
AIDS (London, England)|February 8, 2011
The impact of HIV drug resistance testing on changes to treatmentLoveleen Bansi, Colette Smith, Andrew Phillips, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 17, 2010
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)Loveleen Bansi, Anna Maria Geretti, David Dunn, et al.
Blood|January 18, 2003
The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressorsJustin Stebbing, Brian Gazzard, Louise Kim, et al.
Annals of Internal Medicine|August 17, 2005
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapyMark Bower, Brian Gazzard, Sundhiya Mandalia, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2010
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteersAkil Jackson, Andrew Hill, Rebekah Puls, et al.
Journal of the International AIDS Society|November 15, 2014
Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 yearsBrian Gazzard, Pierre Marie Girard, Giovanni Di Perri, et al.
Journal of Virology|February 28, 2002
Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapyJohn Wilkinson, Alethea Cope, Jas Gill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in UgandaLaura Waters, Andrew Kambugu, Hilda Tibenderana, et al.
Annals of Internal Medicine|December 19, 2007
Brief communication: rituximab in HIV-associated multicentric Castleman diseaseMark Bower, Tom Powles, Sarah Williams, et al.
AIDS (London, England)|August 30, 2008
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapyMário Guimarães Pessôa, Brian Gazzard, Anna K Huang, et al.
Pageof 21

Showing results (141-150 of 206) with videos related to

Sort By:
Pageof 21
AIDS (London, England)|February 8, 2011
The impact of HIV drug resistance testing on changes to treatmentLoveleen Bansi, Colette Smith, Andrew Phillips, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 17, 2010
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)Loveleen Bansi, Anna Maria Geretti, David Dunn, et al.
Blood|January 18, 2003
The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressorsJustin Stebbing, Brian Gazzard, Louise Kim, et al.
Annals of Internal Medicine|August 17, 2005
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapyMark Bower, Brian Gazzard, Sundhiya Mandalia, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2010
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteersAkil Jackson, Andrew Hill, Rebekah Puls, et al.
Journal of the International AIDS Society|November 15, 2014
Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 yearsBrian Gazzard, Pierre Marie Girard, Giovanni Di Perri, et al.
Journal of Virology|February 28, 2002
Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapyJohn Wilkinson, Alethea Cope, Jas Gill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in UgandaLaura Waters, Andrew Kambugu, Hilda Tibenderana, et al.
Annals of Internal Medicine|December 19, 2007
Brief communication: rituximab in HIV-associated multicentric Castleman diseaseMark Bower, Tom Powles, Sarah Williams, et al.
AIDS (London, England)|August 30, 2008
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapyMário Guimarães Pessôa, Brian Gazzard, Anna K Huang, et al.
Pageof 21